

COURSE FACULTY, IAS–USA STAFF, BOARD OF DIRECTORS, AND VIRAL HEPATITIS ADVISORY BOARD FINANCIAL RELATIONSHIPS WITH COMMERCIAL ENTITIES

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, IAS–USA Board members, Viral Hepatitis Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the previous 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity. The **ACCME defines a commercial interest** as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The **ACCME** does not consider providers of clinical service directly to patients to be **commercial interests** – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.” Below are the financial interests that faculty members of this course have had within the past 12 months as of the date listed. View the [Faculty Financial Disclosure Policy](#).

CHARLESTON, SOUTH CAROLINA—NOVEMBER 2, 2018

Workshop Hosts

<p>Divya Ahuja, MD Clinical Associate Professor of Internal Medicine University of South Carolina School of Medicine Columbia, South Carolina</p>	<p><i>Dr Ahuja has no relevant financial affiliations to disclose. (Updated 10/16/18)</i></p>
<p>Eric Meissner, MD, PhD Assistant Professor of Medicine Director of HIV and Hepatitis Patient Care and Research Division of Infectious Diseases Department of Microbiology and Immunology Medical University of South Carolina Charleston, South Carolina</p>	<p><i>Dr Meissner has received grant support awarded to his institution from Gilead Sciences, Inc. (Updated 06/28/18)</i></p>

Workshop Leaders

<p>Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Division of Infectious Diseases Massachusetts General Hospital Boston, Massachusetts</p>	<p><i>Dr Kim has no relevant financial affiliations to disclose. (Updated 10/25/18)</i></p>
<p>Jennifer J. Kiser, PharmD Associate Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora, Colorado</p>	<p><i>Dr Kiser has received funding paid to her institution for an investigator-initiated pharmacokinetic study with Gilead Sciences, Inc. (Updated 10/16/18)</i></p>
<p>Michael S. Saag, MD Professor of Medicine Jim Straley Chair in AIDS Research Director, Center for AIDS Research Associate Dean for Global Health, School of Medicine University of Alabama at Birmingham Birmingham, Alabama</p>	<p><i>Dr Saag has received research grants and support awarded to his institution from and served as scientific advisor to Merck, Proteus, ViiV Healthcare, and Gilead Sciences, Inc. (Updated 09/25/18)</i></p>

IAS–USA CME Staff

<p>Donna M. Jacobsen Executive Director</p>	<p><i>Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 10/25/18)</i></p>
--	--

IAS–USA Board of Directors

The nonstaff members of the IAS–USA Board of Directors are not compensated for their roles in governing and overseeing the IAS–USA. Please see <https://iasusa.org/about/ias-usa-board-of-directors/> for information about board members and a link to up-to-date financial disclosure information.

IAS–USA Viral Advisory Board

The members of the IAS–USA Viral Hepatitis Advisory Board are not compensated for their roles in governing and overseeing the IAS–USA viral hepatitis educational efforts. Please see <https://iasusa.org/activities/live-courses/hepatitis-c-virus-courses/viral-hepatitis-advisory-board/> for information about the financial disclosures for the IAS–USA Viral Hepatitis Advisory Board.